CTNNA1 Mutation: Stomach Cancer Risk & Surgery Options

If your genetic testing revealed a CTNNA1 mutation rather than CDH1, you do not necessarily need to have your stomach removed right away. While CTNNA1 is linked to Hereditary Diffuse Gastric Cancer (HDGC), it is considered a “moderate risk” gene ^[1]. Because of this, the strict recommendation to undergo prophylactic total gastrectomy (preventative stomach removal) between ages 18 and 40 is much less rigid for CTNNA1 carriers than for CDH1 carriers ^[2][3]. Many patients safely opt for long-term endoscopic surveillance instead of immediate surgery ^[4][5].

Understanding Your Risk with CTNNA1

Both CDH1 and CTNNA1 mutations can cause Hereditary Diffuse Gastric Cancer (HDGC) ^[6]. HDGC increases your risk of developing diffuse gastric cancer, a type of stomach cancer that grows throughout the stomach lining rather than forming a single, distinct lump. However, the risk profiles of the two genes are different:

• CDH1 (High Risk): Lifetime risk of stomach cancer is estimated at roughly 70% for men and 56% for women by age 80 ^[7].
• CTNNA1 (Moderate Risk): Lifetime risk is estimated at approximately 49% to 57% by age 80 ^[1][8].

You might be wondering: If a woman with CDH1 has a 56% risk, and my CTNNA1 risk is up to 57%, why is CTNNA1 considered “moderate” while CDH1 is “high”?

This is a very common source of confusion. In clinical genetics, a “high penetrance” gene typically carries a risk above 60%, while “moderate penetrance” genes fall in the 20% to 59% range. More importantly, the 49% to 57% estimate for CTNNA1 comes largely from studies of families with a very strong, well-documented history of stomach cancer ^[1].

If your mutation was found incidentally (for example, on a broad genetic testing panel) and you do not have a strong family history of diffuse gastric cancer, your personal lifetime risk may actually be much lower ^[9]. Additionally, cancer onset in CTNNA1 carriers is generally less predictable and can occur later in life than in CDH1 carriers, which is why doctors do not aggressively push for surgery in young adulthood ^[10][3].

The exact type of CTNNA1 mutation you have also matters. For instance, truncating variants—mutations that prematurely stop the protein from forming—carry a higher risk than other types of mutations ^[1].

Surgery vs. Surveillance for CTNNA1

Because CTNNA1 carries a lower and less predictable risk, the 2020 International Gastric Cancer Linkage Consortium (IGCLC) guidelines recommend a highly individualized approach ^[9]. It is strongly recommended that you make this decision with the help of a specialized HDGC center of excellence or a genetic counselor ^[9][11].

Endoscopic Surveillance

For CDH1 carriers, surveillance is often viewed as a temporary measure to delay surgery. For CTNNA1 carriers, long-term endoscopic surveillance is widely accepted as a safe, permanent alternative to surgery ^[4][5].

This involves an annual specialized endoscopy using the “Cambridge Protocol.” While you are asleep under sedation, a gastroenterologist uses a camera to examine your stomach and takes 30 or more random biopsies (tiny tissue samples) to check for microscopic cancer cells ^[12][13]. Because CTNNA1 carries a lower lifetime risk, many patients choose to rely on this careful monitoring rather than undergoing surgery ^[4]. Your care team will help you determine the right age to begin these annual screenings based on your family history.

Prophylactic Total Gastrectomy

Prophylactic total gastrectomy is the surgical removal of the entire stomach before cancer develops ^[14]. While heavily encouraged for CDH1 carriers, it is generally considered a secondary option for CTNNA1 carriers ^[2][15]. Living without a stomach is life-altering; it involves significant, permanent changes to how you eat and digest food, potential for long-term weight loss, and conditions like dumping syndrome ^[16][11].

You and your care team might still consider surgery if:

• You have a very strong family history of diffuse gastric cancer ^[5].
• Your annual endoscopy finds microscopic foci (tiny spots) of signet ring cell cancer ^[12].
• The daily anxiety of waiting for cancer to develop outweighs the significant physical impacts of living without a stomach ^[11][16].

Breast Cancer Risk

Unlike CDH1 mutations, which carry a high risk of lobular breast cancer, current evidence does not consistently associate CTNNA1 mutations with a significantly increased risk of breast cancer ^[3][10]. Standard screening guidelines apply unless your family history suggests otherwise ^[6]. However, because research on CTNNA1 is continually evolving, it is important to check back with your genetic counselor every few years for updated guidelines.